Myriad possesses the deepest diagnostic pipeline across the disease spectrum, including clinical tests in areas of unmet medical need such as autoimmune diseases, dermatology, neuroscience, oncology, preventative care and urology. Myriad’s research investment totals up to $341.7 million over the past five years.

Stage 1 DISCOVERY

  • myPath ® Bipolar
  • myPath ® Endometriosis